Price Chart

Price Chart

Profile

Scribe Therapeutics, Inc. is a clinical-stage biotechnology company. It is engaged in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded in June 2017 by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Alameda, CA.
URL http://www.scribetx.com
Investor Relations URL N/A
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style N/A
Next Earnings Release Nov. 11, 2026 (est.)
Last Earnings Release N/A
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Scribe Therapeutics, Inc. is a clinical-stage biotechnology company. It is engaged in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded in June 2017 by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Alameda, CA.
URL http://www.scribetx.com
Investor Relations URL N/A
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style N/A
Next Earnings Release Nov. 11, 2026 (est.)
Last Earnings Release N/A
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A